Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis

Evaluating Neurological Outcomes in Neonates Through SSEP: A Review of Current Evidence